Horizon Pharma (HZNP): 8 Person Study Confirms Field Data On Krystexxa - Piper Jaffray
Tweet Send to a Friend
Piper Jaffray analyst, David Amsellem, reiterated his Overweight rating on shares of Horizon Pharma (NASDAQ: HZNP) after polling rheumatologists and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE